1	RESEARCH ARTICLE
2 3 4 5 6 7	Association between the ACE I/D gene polymorphism and progressive renal failure in autosomal dominant polycystic kidney disease: A meta- analysis
7 8 9	Noel Pabalan ^{1*} , Phuntila Tharabenjasin ¹ , Yardnapar Parcharoen ¹ , Adis Tasanarong ^{1, 2}
10 11 12 13 14 15 16 17	 ¹ Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand ² Nephrology Unit, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
18 19 20	* <u>noelpabalan@mail.com</u>
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Short title: Meta-analysis ACE I/D polymorphism progressive renal failure ADPKD
35	
36	
37	
38	
39 40	
40 41	
42	
43	
44	
45	

46 List of abbreviations

47	ABP	Australia Bulgaria Poland
48	ACE	angiotensin converting enzyme gene
49	ACE	angiotensin converting enzyme protein
50	ADPKD	autosomal dominant polycystic kidney disease
51	AM	analysis model
52	BF	Bayes Factor
53	BFR	Belgium France
54	CB	Clark-Baudouin
55	CC	case-control
56	CI	confidence interval
57	CO	cohort
58	CS	cross-sectional
59	D	decreased risk
60	ם חח	variant homozygous genotype
61		dooxyrihonyolojo agid
62		aliminated heterogenaity
63	En	eliminated heterogeneity
64	ES E	fixed offects
04 65	F CC	
05	US UNE	
00	HWE	Hardy-Weinberg Equilibrium
0/	$\frac{1}{r^2}$	increased risk
68		measure of variability
69	I/D	polymorphism
70	ID	heterozygous genotype
71	II	common homozygous genotype
72	LS	lost significance
73	maf	minor allele frequency
74	mRNA	messenger ribonucleic acid
75	Ν	total number of comparisons
76	n	number of studies
77	n	frequency of occurrence
78	OR	odds ratio
79	\mathbf{P}^{a}	P-value for association
80	P^{b}	P-value for heterogeneity
81	PRF	progressive renal failure
82	PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
83	PRO	pre-outlier
84	PSO	post-outlier
85	R	random-effects
86		Reference of studies
87	RNS	retained non-significance
88	RH	reduced heterogeneity
89	ΠΚΔ	United Kingdom Australia
90	USA	United States of America
01	USA	United States of America
91		
92		
93		
<i>))</i>		
94		
95		
00		
96		
97		
00		
98		
99		
100		
100		

101 Abstract

102

103 Objective The angiotensin converting enzyme insertion/deletion (ACE I/D) gene 104 polymorphism is involved in a wide range of clinical outcomes. This makes ACE I/D an 105 important genetic marker. Updating the genetic profile of ACE I/D and raising the evidence 106 for its role in renal disease is therefore needed. Reported associations of ACE I/D with 107 progressive renal failure (PRF) in autosomal dominant polycystic kidney disease (ADPKD) 108 have been inconsistent, prompting a meta-analysis to obtain more precise estimates. 109 Methods Multi-database search yielded 18 articles for inclusion in the meta-analysis. Risks 110 (odds ratios [ORs] and 95% confidence intervals) were estimated by comparing the ACE 111 genotypes (heterozygote ID, homozygotes DD and II). Heterogeneous (random-effects) 112 pooled associations were subjected to outlier treatment which yielded fixed-effects outcomes 113 and split the findings into pre- (PRO) and post- (PSO) outlier status. Subgroup analysis was 114 based on ethnicity (Asian/Caucasian) and minor allele frequency (maf). The ≥ 0.50 maf 115 subgroup indicates higher frequency of the variant II genotype over that of the common DD 116 genotype, otherwise, the subgroup is considered < 0.50 maf. Stability of the associative 117 effects was assessed with sensitivity treatment. Temporal trend of association was examined 118 with cumulative meta-analysis. 119 Results In the PSO analysis, overall effects were null (ORs 0.99-1.02) but not in the 120 subgroups (Asian and ≥ 0.50 maf), where in presence of the D allele (DD/ID) and the I allele 121 (II), increased (ORs 1.63-5.62) and reduced (OR 0.22) risks were observed, respectively. 122 Of these pooled effects, the Asian and ≥ 0.50 maf homozygous DD genotypes had high ORs 123 (5.01-5.63) indicating elevated magnitude of effects that were highly significant (P^a < 10⁻⁵) 124 and homogeneous ($I^2 = 0\%$), in addition to their robustness. In contrast, the Caucasian and 125 < 0.50 maf subgroup effects were: (i) non-heterogeneous (fixed-effects) at the outset, which 126 did not require outlier treatment and (ii) non-significant (ORs 0.91-1.10, $P^a = 0.15-0.79$). 127 Cumulative meta-analysis revealed increased precision of effects over time. 128 **Conclusions** PRF in ADPKD impacted the Asian and ≥ 0.50 maf subgroups where DD 129 homozygote carriers were up to 6-fold susceptible. The high magnitude of these effects 130 were highly significant, homogeneous and robust indicating strong evidence of association. 131 132 Keywords: ACE, I/D polymorphism, progressive renal failure, ADPKD, meta-analysis 133 134 135

136 Introduction

137 138	Autosomal dominant polycystic kidney disease (ADPKD) is an inherited systemic disease
139	characterized by fluid filled cysts in the kidneys leading to end stage renal failure in later
140	years of life [1]. Preventing progressive renal failure (PRF) is mainly treated with controlling
141	blood pressure and reducing proteinuria [2]. However, these reno-protective measures do not
142	benefit all patients [3]. These differential treatment outcomes may in part be attributed to
143	genetics. Studies on mouse and human models suggest that genetic variation plays a
144	significant role in PRF associated with ADPKD [4,5]. One genetic variation is the insertion/
145	deletion (I/D) polymorphism in the angiotensin converting enzyme (ACE) gene, a 24 kb
146	sequence of DNA in intron 16 of chromosome 17q23. This gene encodes the ACE protein,
147	which is found in mammalian tissues and body fluids as ectoenzymes on cell surfaces and in
148	serum [6]. The I/D polymorphism has been shown to determine the levels of circulating ACE
149	enzymes [7]. ACE enzyme levels have been suggested to associate with the ACE genotypes
150	(heterozygote ID, homozygotes DD and II) possibly affecting therapeutic response [8].
151	Individuals carrying the DD homozygote genotype were found to exhibit the highest serum
152	ACE activity when compared to carriers of II homozygote and ID heterozygote genotype
153	who showed low and intermediate activity, respectively [7]. The relationship between ACE
154	activity and ACE genotypes, specifically homozygous DD appears to be the central concept
155	in the clinical genetics of renal disease [9]. In a modification of ACE activity, a meta-analysis
156	of 46 studies revealed that the genotypes (ID, DD) containing the D allele showed higher
157	plasma ACE activity than the homozygous II genotype [10]. In ADPKD patients, the DD
158	homozygote genotype was found to correlate with progression of renal insufficiency [11]. In
159	addition, ADPKD patients have hypertension, a severe complication in which the ACE gene
160	is most likely involved [10]. The value of ACE I/D as a genetic marker lies in its association
161	with risk of a wide range of clinical outcomes that include response to ACE inhibitor therapy

162	[12], cardiovascular diseases [10], diabetes-related [13,14], cancer [15], longevity [16],
163	Alzheimer's disease [17] and muscle performance [18]. The span of ACE involvement in a
164	wide variety of clinical conditions and evidence of elevated ACE activity associated with the
165	ACE D allele prompted a Genome-Wide Association Study (GWAS) from the quantitative
166	trait loci perspective [19], with no mention of ADPKD. Another GWAS profiled ADPKD
167	from an epigenetic perspective [20], with no mention of ACE I/D. Thus, GWAS has involved
168	ACE I/D and ADPKD which were not reported in the same study. One study that examined
169	both ACE I/D and ADPKD was a meta-analysis, which was published in 2006 [21]. Since
170	then, new primary studies have emerged, with inconsistent results. Given the variability of
171	results and length of time (13 years) since the last synthesis, we undertook this meta-analysis
172	for three reasons: (i) obtain less ambiguous, clearer estimates and updated role of ACE I/D
173	with renal failure progression in ADPKD; (ii) apply novel meta-analysis techniques (e.g.
174	outlier treatment) in order to raise the strength of evidence and (iii) examine the cumulative
175	trend of association. Simultaneous application of meta-analysis treatments that focus on the
176	pathophysiological role of ACE I/D precluded inclusion of other polymorphisms in this study.
177	This meta-analysis aims for better understanding of the genetics of PRF in ADPKD, so that it
178	may provide important information that might be useful to decision makers in healthcare,
179	particularly in the field of nephrology.

180

181 Materials and Methods

182

184

183 Selection of studies

185 Two authors (NP and PT) performed primary screening (titles/abstracts) and disagreements 186 were resolved through screening of the title/abstract in question by a third author (YP). Three 187 databases (PubMed in MEDLINE, Google Scholar and Science Direct) were searched for

188	association studies as of March 12, 2019. Terms used were "angiotensin converting enzyme",
189	"ACE", "ADPKD", "autosomal dominant polycystic kidney disease" and "polymorphism" as
190	medical subject heading and text, restricted to the English language. Additional eligible
191	studies were identified from references cited in the retrieved articles. Inclusion criteria were:
192	(i) case–control study design evaluating the association between ACE I/D and PRF in
193	ADPKD and (ii) sufficient genotype or allele frequency data to allow calculation of odds
194	ratios (ORs) and 95% confidence intervals (CIs). Exclusion criteria are: (i) studies without
195	controls or studies whose genotype or allele frequencies were unusable/absent; (ii) those that
196	did not cover the polymorphism or disease in question, (iii) reviews and (iv) non-English
197	articles (S1 List).

- - - -

- 198 **S1 List** Excluded studies
- 199 Data extraction

200 Two investigators independently extracted the data that resulted in consensus. Extracted

201 information from each article included the first author's name, publication year, country of

202 origin, ethnicity, study design and whether the articles addressed the Hardy-Weinberg

203 Equilibrium (HWE). Articles which were not included in a previous meta-analysis [21] are

204 indicated by an asterisk under the author column (Table 1). Primary study authors were

205 contacted in order to obtain more information on incomplete data. Less than a third of the

206 included studies mentioned influence of the environment, but data were not provided.

207 Data distribution, power calculations and HWE assessment

208 Data distribution was assessed with the Shapiro-Wilks (SW) test using SPSS 20.0 (IBM

209 Corp., Armonk, NY, USA). Normal distribution (P > 0.05) warranted descriptive and

210 inferential expressions of mean \pm standard deviation (SD) and the parametric approach,

211 respectively. Otherwise, the median (with interquartile range) and non-parametric tests were

used, respectively. Using the G*Power program [22], we evaluated statistical power as its

213	adequacy	bolsters th	e level o	f associative	evidence.	Assuming a	an OR o	of 1.5 at a	genotypic

- risk level of $\alpha = 0.05$ (two-sided), power was considered adequate at $\ge 80\%$. HWE was
- assessed using the application in <u>https://ihg.gsf.de/cgi-bin/hw/hwa1.pl</u>.
- 216 Methodological quality of the studies
- 218 We used the Clark-Baudouin (CB) scale to evaluate methodological quality of the included
- 219 studies [23]. The CB criteria include P-values, statistical power, correction for multiplicity,
- 220 comparative sample sizes between cases and controls, genotyping methods and the HWE. In
- this scale, low, moderate and high have scores of < 5, 5-6 and \geq 7, respectively.

Genetic models

- From the 18 included studies [24-41], minor allele frequency (maf) of the homozygous II
- 224 genotype among controls was < 0.50 in 11 of them [25,30-33,35-37,39-41] and not (≥ 0.50)
- the remaining seven [24,26-29,34,38]. Non-uniformity of the maf across the studies (S1
- Table) influenced our study design in two ways: (1) maf data were dichotomized into
- $\geq 0.50 \text{ maf}$ (DD < II) and < 0.50 maf (DD > II) and (2) precluded the use of standard genetic
- 228 modeling. Thus, we opted for the allele-genotype model, wherein we compared (i) DD
- 229 homozygotes with the ID/II genotype; (ii) II homozygotes with ID/DD genotype and
- 230 (iii) heterozygous ID genotype carriers with homozygotes of the II and DD genotypes.

231 **S1 Table** Quantitative features of the included studies

232

217

233 Data synthesis

Risks of PRF in ADPKD (using raw data for frequencies) were estimated for each study and

- comparing the effects on the same baseline, we calculated pooled ORs. We performed a
- cumulative meta-analysis to examine changes in the pooled ORs with accumulation of data
- over time. Subgrouping was ethnicity-based (Asians and Caucasians) and maf-based (≥ 0.50
- 239 maf and < 0.50 maf). To assess the strength of evidence, we used three indicators: First, the

240 magnitude of effects are higher or lower when the pooled ORs are farther from or closer to 241 the OR value of 1.0 (null effect), respectively [42]. Second, the P-value is contextualized 242 from the Bayesian perspective of the Bayes Factor (BF). The BF compares support from the 243 null and alternate hypotheses, in contrast to the P-value, which addresses the null only [43]. 244 Thus, P-values (Z-scores) of 0.05 and 0.001 (corresponding to minimum BFs of ≥ 0.15 and 245 0.005) indicate moderate and strong (to very strong) evidence, respectively [44]. The BF rests 246 on the likelihood paradigm [45], indicative of how strong the hypotheses are supported by the 247 data [43]. Thus, the likelihoods between the absence (null hypothesis) and presence (alternate 248 hypothesis) of association of ACE I/D with PRF in ADPKD are compared. Third, 249 homogeneity is preferred to heterogeneity, but heterogeneity is unavoidable [46]. Thus, occurrence of heterogeneity between studies was estimated with the χ^2 -based Q test [47], 250 with threshold of significance set at $P^b < 0.10$. Heterogeneity was also quantified with the I^2 251 statistic which measures variability between studies [48]. I^2 values of > 50% indicate more 252 253 variability than those $\leq 50\%$ with 0% indicating zero heterogeneity (homogeneity). Evidence 254 of functional similarities in population features of the studies warranted using the fixed-255 effects model [49], otherwise the random-effects model [50] was used. Sources of 256 heterogeneity were detected with the Galbraith plot [51] followed by re-analysis (outlier 257 treatment). Of note, outlier treatment dichotomized the comparisons into pre-outlier (PRO) 258 and post-outlier (PSO). Sensitivity analysis, which involves omitting one study at a time and 259 recalculating the pooled OR, was used to test for robustness of the summary effects. We 260 assessed publication bias for comparisons that met two conditions: (i) ≥ 10 studies only [52] 261 and (ii) significant outcomes. Except for heterogeneity estimation [47], two-sided P-values of 262 ≤ 0.05 were considered significant. All associative outcomes were Bonferroni-corrected in 263 order to control for Type 1 error. Data for the meta-analysis were analyzed using Review

264 Manager 5.3 (Cochrane Collaboration, Oxford, England), SIGMASTAT 2.03, and SIGMAPLOT

265 11.0 (Systat Software, San Jose, CA).

266

267 **Results**

268

270

- 269 Search results and study features
- 271 Figure 1 outlines the study selection process in a PRISMA-sanctioned flowchart (Preferred
- 272 Reporting Items for Systematic Reviews and Meta-Analyses). Initial search resulted in 548
- 273 citations, followed by a series of omissions (S1 List) that eventually yielded 18 articles for
- 274 inclusion [24-41].
- 276 **Fig 1** Summary flow chart of literature search
- 278 **S1 List** Excluded studies
- 279

282

275

277

280281 Characteristics of the included studies

283 Table 1 shows that the number of Caucasian (n = 12) studies was twice that of the Asians (n 284 = 6). Methodological quality of the component studies was moderate based on mean and SD 285 (6.37 ± 1.24) of the normally distributed CB scores (SW test: P = 0.33). S1 Table shows the 286 quantitative features of the included studies, specifically the differential frequencies of the 287 ACE genotypes between the race subgroups, where II was higher (83%: 5/6) in the Asian 288 studies and lower (17%: 2/12) in the Caucasian studies. Adequate statistical power was 289 absent in the Asian studies, and present in two Caucasian studies [31,34]. At the aggregate 290 level, however, power in both ethnic subgroups was > 80% (Asian: 97.3%; Caucasian: 291 100.0%). Control frequencies deviated from the HWE in four studies [27,28,36,41]. This 292 meta-analysis followed the PRISMA and genetic association guidelines (S2-S3 Tables).

- 293
- 294

S1 Table Quantitative features of the included studies

- S2 Table PRISMA checklist

- 299 S3 Table Meta-analysis checklist

Table 1 Characteristics of the included studies that examined ACE I/D polymorphism

303 associations with PRF in ADPKD

First author	[R]	Year	Country	Ethnicity	Study design	Addressed HWE	СВ
Konoshita	[24]	2001	Japan	Asian	CS	Yes	7
Lee	[25]	2000	Korea	Asian	CS	NM	5
Ramanathan *	[26]	2016	India	Asian	CC	Yes	6
Tripathi	[27]	2006	India	Asian	CC**	NM	7
Tripathi *	[28]	2008	India	Asian	CC**	NM	8
Uemasu	[29]	1997	Japan	Asian	CC	NM	5
Baboolal	[30]	1997	UKA	Caucasian ^a	CS	Yes	7
Buraczynska *	[31]	2006	Poland	Caucasian	CC**	Yes	7
Ecder	[32]	2003	USA	Caucasian	CS	Yes	8
Gumprecht *	[33]	2007	Poland	Caucasian	CS	NM	4
Lovati *	[34]	2001	Switzerland	Caucasian ^a	CC**	Yes	9
Merta	[35]	2003	Czechoslovakia	Caucasian	CC	Yes	5
Perez-Oller	[36]	1999	Spain-	Caucasian	CS	NM	6
Persu	[37]	2003	BFR	Caucasian	CS	Yes	6
Saggar-Malik	[38]	2000	UK	Caucasian	CO	NM	6
Schiavello	[39]	2001	ABP	Caucasian	CS	Yes	6
van Dijk *	[40]	2000	Netherlands	Caucasian	CC**	Yes	6
Wanic-Kossowska *	[41]	2014	Poland	Caucasian	CC**	NM	7
	First author Konoshita Lee Ramanathan * Tripathi Tripathi * Uemasu Baboolal Buraczynska * Ecder Gumprecht * Lovati * Merta Perez-Oller Persu Saggar-Malik Schiavello van Dijk *	First author[R]Konoshita[24]Lee[25]Ramanathan *[26]Tripathi[27]Tripathi *[28]Uemasu[29]Baboolal[30]Buraczynska *[31]Ecder[32]Gumprecht *[33]Lovati *[34]Merta[35]Perez-Oller[36]Persu[37]Saggar-Malik[38]Schiavello[40]Wanic-Kossowska *[41]	First author [R] Year Konoshita [24] 2001 Lee [25] 2000 Ramanathan * [26] 2016 Tripathi [27] 2006 Tripathi * [28] 2008 Uemasu [29] 1997 Baboolal [30] 1997 Buraczynska * [31] 2006 Ecder [32] 2003 Gumprecht * [33] 2007 Lovati * [34] 2001 Merta [35] 2003 Perez-Oller [36] 1999 Persu [37] 2003 Saggar-Malik [38] 2001 Van Dijk * [40] 2001	First author[R]YearCountryKonoshita[24]2001JapanLee[25]2000KoreaRamanathan *[26]2016IndiaTripathi[27]2006IndiaTripathi *[28]2008IndiaUemasu[29]1997JapanBaboolal[30]1997UKABuraczynska *[31]2006PolandEcder[32]2003USAGumprecht *[33]2007PolandMerta[35]2003SwitzerlandMerta[36]1999Spain-Persu[37]2003BFRSaggar-Malik[38]2000UKSchiavello[39]2001ABPvan Dijk *[40]2004NetherlandsWanic-Kossowska *[41]2014Poland	First author[R]YearCountryEthnicityKonoshita[24]2001JapanAsianLee[25]2000KoreaAsianRamanathan *[26]2016IndiaAsianTripathi[27]2006IndiaAsianTripathi *[28]2008IndiaAsianUemasu[29]1997JapanAsianBaboolal[30]1997UKACaucasian aBuraczynska *[31]2006PolandCaucasianGumprecht *[33]2007PolandCaucasianMerta[34]2001SwitzerlandCaucasianPersu[36]1999Spain-CaucasianSaggar-Malik[38]2000UKCaucasianSchiavello[39]2001ABPCaucasianvan Dijk *[40]2000NetherlandsCaucasianWanic-Kossowska *[41]2014PolandCaucasian	First author[R]YearCountryEthnicityStudy designKonoshita[24]2001JapanAsianCSLee[25]2000KoreaAsianCSRamanathan *[26]2016IndiaAsianCC**Tripathi[27]2006IndiaAsianCC**Tripathi *[28]2008IndiaAsianCC**Uemasu[29]1997JapanAsianCC**Baboolal[30]1997UKACaucasian aCSBuraczynska *[31]2006PolandCaucasian aCS**Gumprecht *[33]2007PolandCaucasian aCS**Iovati *[34]2003USACaucasian aCC**Merta[35]2003SwitzerlandCaucasian aCC**Persu[36]1999Spain-Caucasian aCC**Persu[37]2003BFRCaucasian aCSSaggar-Malik[38]2000UKCaucasianCSSchiavello[39]2011ABPCaucasianCSvan Dijk *[40]2000NetherlandsCaucasianCS**	First author[R]YearCountryEthnicityStudy designAddressed HWEKonoshita[24]2001JapanAsianCSYesLee[25]2000KoreaAsianCSNMRamanathan *[26]2016IndiaAsianCC*YesTripathi[27]2006IndiaAsianCC**NMTripathi *[28]2008IndiaAsianCC**NMUemasu[29]1997JapanAsianCC**NMBaboolal[30]1997UKACaucasianCS**YesBuraczynska *[31]2006PolandCaucasianCS**YesEcder[32]2003USACaucasianCS**YesGumprecht *[33]2007PolandCaucasianCC**YesMerta[35]2003CzechoslovakiaCaucasianCC**YesPerez-Oller[36]1999Spain-CaucasianCSYesPersu[37]2003BFRCaucasianCSYesSaggar-Malik[38]2000UKCaucasianCSYesSchiavello[39]2001ABPCaucasianCC**YesVan Dijk *[40]2000NetherlandsCaucasianCC**YesVan Dijk *[41]204PolandCaucasianCC**Yes

ACE: angiotensin converting enzyme gene; I/D: polymorphism; PRF: progressive renal failure; ADPKD: autosomal
 dominant polycystic kidney disease; [R]: reference number of the studies; UKA: United Kingdom Australia; USA: United
 States of America; BFR: Belgium France; ABP: Australia Bulgaria Poland; CS: cross-sectional; CC: case-control; CO:
 cohort; ** diluted cases (ADPKD was one of the disease conditions of the patients); HWE: Hardy-Weinberg Equilibrium;
 NM: not mentioned; CB: Clark-Baudouin; *not in the Pereira (2006) meta-analysis; Caucasian ^a: admixed population



318 Meta-analysis outcomes

- 320 The overall PRO homozygote DD genotype outcome indicating increased risk (OR 1.37)
- 321 was marginally significant ($P^a = 0.05$) and nullified in the PSO analysis (OR 1.02, $P^a = 0.78$).
- 322 HWE analysis validated the overall outcomes (Table 2). In the subgroups (Table 3), seven
- 323 associative outcomes (Asian and ≥ 0.50 maf) were statistically significant, moderate in PRO
- 324 ($P^a = 0.01-0.02$) and high in PSO ($P^a < 10^{-4}$ to 10^{-5}). The PSO outcomes survived the
- 325 Bonferroni-correction, but the PRO did not. The highly significant PSO outcomes had the
- following features: (i) all were homogeneous ($I^2 = 0\%$); (ii) magnitude of the homozygote
- 327 DD increased risk effects was more (ORs 5.01-5.62) than that in heterozygote ID (ORs 1.63-
- 328 1.68); and (iii) the pooled homozygote II effect indicated reduced risk (OR 0.22). In contrast,
- 329 Caucasian and < 0.50 maf outcomes were non-associative between ACE I/D and PRF in
- 330 ADPKD (ORs 0.91-1.10, 95% CI 0.79-1.31, $P^a = 0.15-0.79$), and initially non-heterogeneous
- 331 (fixed-effects) which precluded outlier treatment (Table 3).

332 Table 2 Overall and modified outcomes of ACE I/D effects on PRF in ADPKD

	Test of association					Test of heterogeneity			Test of association				Test of heterogeneity			Effect of outlier treatment		
	n	OR	95% CI	P ^a	Risk	P ^b	l² (%)	AM	n	OR	95% CI	P^{a}	Risk	P⁵	l² (%)	AM	Signi- ficance	Hetero geneity
				PR	0							PSC)					
Overall																	•	
DD	18	1.37	1.00-1.88	0.05*	I	10 ⁻⁵	82	R	15	1.02	0.90-1.16	0.78	Null	0.27	0	F	LS	EH
ID	18	0.96	0.78-1.19	0.70	D	10 ⁻⁵	89	R	15	1.01	0.88-1.15	0.91	Null	0.24	19	F	RNS	RH
II	18	0.83	0.59-1.18	0.30	D	10 ⁻⁵	84	R	13	0.99	0.85-1.16	0.95	Null	0.15	29	F	RNS	RH
HWE																		
DD	14	1.14	0.91-1.42	0.27	I	0.01	53	R	12	0.99	0.84-1.16	0.87	Null	0.27	18	F	RNS	RH
ID	14	0.96	0.86-1.08	0.51	D	0.11	34	F										
П	14	0.83	0.63-1.08	0.17	D	0.0009	63	R	13	1.00	0.87-1.15	0.95	Null	0.20	24	F	RNS	RH

ACE: angiotensin converting enzyme gene; I/D: polymorphism; PRF: progressive renal failure; ADPKD: autosomal dominant polycystic kidney disease; DD and II: homozygote genotypes; ID: heterozygote genotype; HWE: Hardy-Weinberg Equilibrium; n: number of studies; OR: odds ratio; CI: confidence interval; P^a: P-value for association; I: increased risk; D: decreased risk; Null ORs = 0.97-1.03; P^b: P-value for heterogeneity; I²: measure of variability; AM: analysis model; R: random-effects; F: fixed-effects; PRO: pre-outlier; PSO: post outlier; LS: lost significance; RNS: retained non-significance; EH: eliminated heterogeneity; RH: reduced heterogeneity; values in bold indicate significant associations; *did not survive the Bonferroni correction

350 Table 3 Subgroup effects of the ACE I/D polymorphism on PRF in ADPKD

351

352

		Test of association					Test of heterogeneity			Test of association				Test of heterogeneity			Effect of outlier treatment	
	n	OR	95% CI	P^{a}	Risk	P^b	Ι ² (%)	AM	n	OR	95% CI	P^{a}	Risk	P ^b	l ² (%)	AM	Signi-	Hetero-
	PRO)				PSO								geneity	
Asian																		
DD	6	2.84	1.25-6.44	0.01*	I	10 ⁻⁴	83	R	4	5.62	3.93-8.04	10 ⁻⁵	I	0.96	0	F	ES	EH
ID	6	1.13	0.58-2.20	0.73	I	10 ⁻⁵	87	R	5	1.63	1.27-2.10	10 ⁻⁴	I	0.61	0	F	GS	EH
II	6	0.48	0.22-1.04	0.06	D	10 ⁻⁵	89	R	3	0.22	0.16-0.29	10 ⁻⁵	D	0.44	0	F	GS	EH
Caucasia	an																	
DD	12	1.02	0.89-1.16	0.79	Null	0.18	27	F										
ID	12	0.92	0.81-1.03	0.15	D	0.22	23	F										
II	12	1.09	0.95-1.26	0.23	I	0.24	21	F										
≥ 0.50 m	af (DD < II)																
DD	7	2.73	1.21-6.18	0.02*	I	10 ⁻⁵	91	R	5	5.01	3.60-6.96	10 ⁻⁵	I	0.49	0	F	ES	EH
ID	7	1.01	0.62-1.64	0.97	Null	10 ⁻⁵	85	R	4	1.68	1.29-2.18	10 ⁻⁴	I	0.54	0	F	GS	EH
II	7	0.52	0.26-1.04	0.07	D	10 ⁻⁵	92	R	4	1.05	0.85-1.29	0.65	I	0.27	23	F	RNS	RH
< 0.50 m	af (DD > I	l)																
DD	. 11	1.03	0.88-1.19	0.73	Null	0.35	10	F										
ID	11	0.91	0.79-1.04	0.17	D	0.22	23	F										
11	11	1.10	0.92-1.31	0.28	I	0.21	25	F										

ACE: angiotensin converting enzyme gene; I/D: polymorphism; PRF: progressive renal failure; ADPKD: autosomal dominant polycystic kidney disease; DD and II: homozygote genotypes; ID: heterozygote genotype; maf: minor allele frequency; n: number of studies; OR: odds ratio; CI: confidence interval; P^a: P-value for association; I: increased risk;

5 D: decreased risk; Null: ORs = 0.97-1.03; P^b: P-value for heterogeneity; I²: measure of variability; AM: analysis model; R: random-effects; F: fixed-effects; PRO: pre-outlier;

56 PSO: post outlier; ES: elevated significance; GS: gained significance; RNS: retained non-significance; EH: eliminated heterogeneity; RH: reduced heterogeneity; values in bold

ACE: angiotensin converting enzyme gene; I/D: polymorphism; PRF: progregenotypes; ID: heterozygote genotype; maf: minor allele frequency; n: number D: decreased risk; Null: ORs = 0.97-1.03; P^b: P-value for heterogeneity; I²: r PSO: post outlier; ES: elevated significance; GS: gained significance; RNS: indicate significant associations; * did not survive the Bonferroni correction

358	Mechanism and impact of outlier treatment
359 360	The mechanism of outlier treatment for the homozygous DD genotype in the Asian subgroup
361	is visualized in Figs 2-4. Fig 2 shows the PRO forest plot, moderately significant (OR 2.84,
362	95% CI 1.25-6.44, $P^a = 0.01$) and heterogeneous ($P^b < 10^{-4}$, $I^2 = 83\%$). The Galbraith plot
363	identifies two studies [25,26] as the sources of heterogeneity (outliers), located below the -2
364	confidence limit (Fig 3). In Fig 4, the PSO outcome (outliers omitted) shows eliminated
365	heterogeneity ($P^b = 0.96$, $I^2 = 0\%$); intensified increased risk effect (OR 5.62, 95% CI 3.93-
366	8.04) and escalated significance ($P^a < 10^{-5}$). This operation is numerically summarized in
367	Table 2.
368 369 370 371	Fig 2 Forest plot outcome of the Asian <i>ACE</i> homozygous DD effects on PRF in ADPKD
372 373 374	Fig 3 Galbraith plot analysis for the <i>ACE</i> homozygous DD genotype in the Asian subgroup
375 376 377	Fig 4 Forest plot outcome of outlier treatment on the Asian <i>ACE</i> homozygous DD effects on PRF in ADPKD
378 379	Sensitivity analysis and publication bias
380	The high magnitude (OPs 5.01.5.62) of the homoguasts DD Asian and > 0.50 mef offsate
381	The high magnitude (ORS 5.01-5.62) of the homozygote DD Asian and ≥ 0.50 mar effects
382	were robust, but not the heterozygote ID and homozygote II genotypes (Table 4). In the DD
383	homozygote genotype, the Asian effects were more robust than the ≥ 0.50 maf subgroup
384	(Table 4). Thus, the Asian DD effects were more stable than that in ≥ 0.50 maf.
385	Only the PRO overall analysis for the homozygous DD genotype was eligible for
386	publication bias assessment. Non-normal distribution (SW test: $P < 10^{-4}$) of its operating data
387	(ORs) prompted the use of Begg-Mazumdar test of correlation [53] which showed no
388	evidence of publication bias (Kendall's $\tau = 0.23$, P = 0.19).
389 390	

391	Table 4 Sensitivity	analysis of significant ACE	I/D ADPKD outcomes
	,	, ,	

392

Comparison	Geno- type	PRO	PSO	A	В
Overall	DD	Robust	Robust	0	2
Asian	DD	Robust	Robust	0	2
Asian	ID		[28]	1	0
Asian	II		[24,26]	2	0
≥ 0.50 maf	DD	[27,29,38]	Robust	3	1
≥ 0.50 maf	ID		[28]	0	1
A		3	4		
В		2	3		

393 ACE: angiotensin converting enzyme gene; I/D: polymorphism; ADPKD:

autosomal dominant polycystic kidney disease; maf: minor allele frequency;

395 DD and II: homozygote genotypes; ID: heterozygote genotype; A: Number

396 of references contributing to non-robustness; numbers in brackets indicate

397 references that contributed to non-robustness; B: Number of robust outcomes;

398 PRO: pre-outlier; PSO: post-outlier

399

401

400 Cumulative meta-analysis

402 Fig 5 outlines the trend of pooled effects from 1997 to 2016. Here, the "decline effect" is

403 apparent where initial studies show the early extreme phenomenon [54] compared with the

404 subsequent and modulated pooled ORs. Significance was observed in the early studies (1997-

405 1999), lost in the subsequent ones (2000-2006), and then regained in the recent studies (2008-

406 2016). A trend of increasing precision (narrowing of the CIs) is readily observed in the graph.

407

408 **Fig 5** Cumulative meta-analysis of the associations between the *ACE* homozygous 409 DD genotype and PRF in ADPKD

410 411

412 **Discussion**

413

415

414 Summary of associations

- 416 Evidence of association between the *ACE* homozygous DD genotype and risk of PRF in
- 417 ADPKD is tenuous in the overall analysis but strong in the subgroups (Asian and ≥ 0.50) at
- 418 the PSO level. This strength rests on the three indicators: (i) high magnitude of effects (up to

419 5.6-fold), which were (ii) homogeneous (indicating combinability of the studies) and (iii) 420 highly significant (up to $P^a < 10^{-5}$). Of note in the Asian subgroup, the II homozygous effect 421 indicating 78% reduced risk also met the high strength of evidence criteria (Table 3), but was 422 found to be non-robust, which contrasted with robustness of the homozygous DD effect. Our 423 use of subgroup analysis and outlier treatment have unraveled significant and homogeneous 424 associations in three contexts, (i) not achieved in a previous meta-analysis; (ii) neither present 425 in the overall analysis; (iii) nor in the component single-study outcomes. However, the 426 process of subgrouping and performing outlier treatment reduced the number of studies and 427 sample sizes of the comparisons. These may decreased statistical power and risked Type 1 428 error, especially in light of a few (three to five) PSO studies generating multiple significant 429 outcomes in the subgroup analyses. Fortunately, adequate statistical powers of the three to 430 five Asian studies (82.2-97.3%) and their P-values surviving the Bonferroni correction served 431 to minimize the possibility of false-positives and increase confidence in the outcomes. Non-432 associative outcomes in previous primary studies may be attributed to their lack of power and 433 small sample sizes. Underpowered outcomes appear to be common in candidate gene studies 434 [55] and are prone to the risk of Type 1 error. Other highlights of our findings are differential 435 effects between the ethnic (Asian versus Caucasian) and maf (≥ 0.50 versus < 0.50) 436 subgroups. Significant outcomes in Asian but not in Caucasians may be attributed to 437 differences in maf between the two ethnicities [56].

438 Cumulative meta-analysis

439 Studies on associations between ACE I/D and PRF in ADPKD from the last 20 years

440 produced outcomes that reduced the magnitude and retained the heterogeneity of

441 associations. On the other hand, the sustained increased precision and cumulative

significance of effects as well as increase in the number of studies may help establish

443 evidence of association.

444 Comparison with other meta-analyses

445 Five previous meta-analyses relate to our study, four of them not as direct as the fifth. The 446 first [57] focused on angiotensin II types 1 and 2 receptor genes (AGTR1 and AGTR2) in 447 various renal diseases that did not include ADPKD. The second to the fourth meta-analyses 448 [13,14,58] focused on ACE I/D with the outcome of end-stage renal disease (ESRD). All 449 three demonstrated associations of ACE I/D with ESRD, two of which drew race-specific 450 conclusions, one for Caucasians [58] and the other for Asians [14]. The fifth [21] directly 451 relates to our study which was published 13 years ago (2006); the features of both are 452 outlined in Table 4. Pereira et al [21] included non-English articles and meeting abstracts, 453 which we did not in our study because we evaluated methodological quality of the included 454 studies. Methodology-wise, Pereira et al used the recessive model (homozygous DD versus 455 heterozygous ID + homozygous II genotypes) versus the genotype model (homozygous DD, 456 and II, heterozygous ID) in ours. Comparative outcomes are based on the homozygous DD 457 genotype (Table 5). Three differences mark the overall analyses (ours and the previous): (i) 458 the number of studies (18 versus eight); (ii) significance of outcome ($P^a = 0.05$ versus P =459 0.21) and (iii) magnitude of outcome (1.4-fold versus 1.2-fold). In the racial subgroups, 460 Pereira et al showed no material differences between the Asian and Caucasian outcomes 461 (both indicated non-significant increased risks, randomly-derived). In contrast, our outcomes 462 differentiated between the Asians and Caucasians (up to 6-fold versus null). In the Asian outcomes, ours and the previous differed in terms of: (i) significance ($P^a = 0.01 - 10^{-4}$ versus P 463 464 = 0.23) and magnitude of effect (up to 5.6-fold versus 1.6-fold). In the Caucasian analyses, 465 ours versus previous differed in the number of studies (12 versus four) and outcomes (null 466 versus 1.2-fold). 467 468

469

470 **Table 4** Comparison of features between the two meta-analyses

471

	This study	Pereira et al [21]
General features		
Year	2019	2006
Country	Thailand	Brazil
Subgroups	Race/minor allele frequency	Race
Genetic modeling	Allele/Genotype	Recessive
Methods / Treatments		
HWE as inclusion criterion	Yes	No
Modifier analysis	Yes	No
Outlier analysis	Yes	No
Heterogeneity	Q statistic, I ²	Q statistic
Sensitivity analysis	Yes	No
Publication bias	Yes	Yes

472 HWE: Hardy-Weinberg Equilibrium

Table 5 Comparison of outcomes between the current meta-analysis and the 2006 meta-analysis 473

This study									Pereira et al [21]						
Con	Comparison Homozygous DD genotype								Homoz	ygous DD ve homozygo	ersus h us II ge	eterozyg enotypes	jous ID ;)+	
		n	OR	95% CI	P^{a}	Effect	P^{b}	AM	n	OR	95% CI	P ^a	Effect	P ^b	AM
All	PRO	18	1.37	1.00-1.88	0.05*	I	10 ⁻⁵	R		4.00	0.00.1.00	0.04		0.00	Р
	PSO	15	1.02	0.90-1.16	0.78	Null	0.27	F	8	1.23	0.89-1.80	0.21	I	0.29 i	ĸ
Asian	PRO	6	2.84	1.25-6.44	0.01*	I	10 ⁻⁴	R	4	1 50	0.75.0.04	0.00	I	0.70	Р
	PSO	4	5.63	3.93-8.04	10 ⁻⁴	I	0.96	F	4	06.1	0.75-3.24	0.23		0.79	ĸ
Caucasian		12	1.02	0.89-1.16	0.79	Null	0.18	F	4	1.17	0.76-1.80	0.47	I	0.09	R

ACE: angiotensin converting enzyme gene; I/D: polymorphism; DD and II: homozygote genotypes; ID: heterozygote genotype; PRO: pre-outlier; PSO: post-outlier; n: number of studies; OR: odds ratio; CI: confidence interval; P^a: P-value for association; I: increased risk; Null: ORs = 0.97-1.03; 474

475

P^b: P-value for heterogeneity; AM: analysis model; R: random-effects; F: fixed-effects; values in bold indicate significant associations; *did not survive 476

477 the Bonferroni correction

478 Genetic correlates

479

480 Understanding the impact of ACE I/D on renal disease might clarify the role of the

- 481 homozygous DD genotype in PRF and/or variable responses to renoprotective therapy.
- 482 Based on the evidence that the homozygous DD genotype elicits high ACE activity [7], it
- 483 was hypothesized that the homozygous DD genotype were resistant to renoprotective therapy
- 484 [9]. However, it has also been hypothesized that ACE I/D is in linkage disequilibrium with an
- 485 unknown DNA section containing a silencer motif that could inhibit ACE mRNA translation
- 486 [59,60]. This suggests variability of ACE expression at the DNA/mRNA level. Studies have
- 487 reported increased ACE mRNA expression in homozygous DD genotype patients in renal
- 488 [61] and other tissues [62,63]. It is then possible to identify different polymorphisms in the
- 489 ACE gene to identify patients at risk for PRF or therapy resistance. Evidence for the
- 490 association between serum ACE levels and ADPKD has not been consistent [33,39]. The
- 491 numerous studies that examined associations at the gene level had conflicting outcomes. An
- 492 association between the D allele of ACE I/D among ADPKD patients has been detected in
- 493 various populations [24,30,37,40], but not in others [25,29,32,33,35,36,39].
- 494

495 496

ACE gene, ACE protein and RAAS

497 The renin-angiotensin aldosterone system (RAAS) is critical in regulating blood pressure and 498 electrolyte balance [64,65]. The activity of RAAS system in turn, is regulated by the ACE 499 protein where it mediates the rate of production of angiotensinogen from renin [66]. RAAS is 500 activated in progressive kidney disease leading to hypertension [67]. The role of hypertension 501 in the progression of kidney deterioration in ADPKD places the ACE I/D polymorphism at 502 the core of this research. On a morphological level, the pathophysiology of ADPKD involves 503 RAAS where it directly stimulates the growth of renal cysts [68]. Angiotensin II, a RAAS 504 component was observed within cysts and tubules leading to the cyst expansion [69].

505 Strengths and limitations

506

507 Interpreting our findings should consider its limitations and strengths. Limitations include: 508 (i) Eighty-nine percent of the component studies were underpowered; (ii) of the 29 509 comparisons, 22 (76%) were heterogeneous; (iii) pathological conditions of the some cases 510 were diluted, where ADPKD comprised part of the patients' condition and (iv) despite the high significance ($P^a < 10^{-5}$) and magnitude (5-fold) as well as homogeneity ($I^2 = 0\%$) of the 511 512 homozygous DD PSO pooled effects in the Asian and ≥ 0.50 maf comparisons, their wide 513 CIs (3.60-8.04), suggests imprecision which may have compromised the durability of effects. 514 Larger sample sizes may be needed to ameliorate this limitation [70]. Of note, precision in 515 this study had opposing effects, reduced (wide CIs) with subgroup treatment but increased 516 (narrow CIs) with cumulative meta-analysis. The methodology may explain this paradox in 517 terms of sample size and number of studies (n), which was reduced with subgroup analysis 518 but increased with cumulative meta-analysis. 519 On the other hand, the strengths comprise of the following: (i) the combined sample 520 sizes of the overall and subgroups translated to high statistical power; (ii) ten (56%) of the 521 18 articles addressed HWE concerns. Confining the analysis to studies in HWE did not 522 materially alter the pooled ORs; in fact, HWE-analysis validated the overall pooled effects. 523 Given this outcome, the risk of genotyping errors appears to be a minor issue which 524 minimizes methodological weakness in our study; (iii) outlier treatment reduced and 525 eliminated heterogeneity and enabled significance; (iv) the significant PSO ORs in the Asian 526 and ≥ 0.50 maf subgroups survived the Bonferroni correction, thus minimizing the possibility 527 of a Type 1 error; (v) sensitivity treatment conferred robustness to the overall and Asian 528 homozygous DD findings and (vi) publication bias was not evident in the PRO overall 529 comparison.

530

531 Conclusions

- 532
- We have shown that associations of *ACE* I/D with PRF in ADPKD are genotype dependent.
 Substantial amount of evidence presented here may render *ACE* I/D useful as prognostic
 markers for PRF in ADPKD. In spite of the evidence for associations, the complexity of
- 536 ADPKD involves interactions between genetic and non-genetic factors allowing for the
- 537 possibility of environmental involvement. Gene-gene and gene-environment interactions
- base have been reported to have roles in associations of other polymorphisms with ADPKD. All
- but five [29,32,38,39,41] of the 18 articles acknowledged gene-environment interaction.
- 540 Addressing gene-gene and gene-environment interactions [71] may help address the
- 541 pathophysiological significance of ACE I/D and PRF in ADPKD. Four of the included
- articles mentioned haplotype analysis [26,27,35,39] with one presenting haplotype data [26].
- 543 Focus on *ACE* haplotypes have been suggested for future association studies [72]. Additional
- 544 well-designed studies exploring other parameters would confirm or modify our results in this
- study and add to the extant knowledge about the association of the ACE polymorphism and
- 546 PRF in ADPKD.
- 547
- 548 549
- 550
- 551
- 552
- 553
- 554
- 555 556
- 557

558

- 559
- 560
- 561

	Deferences
562	References
563	
564	1. Sun Y, Zhou H, Yang BX (2011) Drug discovery for polycystic kidney disease. Acta Pharmacol Sin
363 566	32: 805-816.
300 567	2. Remuzzi G, Ruggenenti P, Benigni A (1997) Understanding the nature of renal disease
568	3 Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, et al. (2003) Progression of chronic kidney
569	disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme
570	inhibition: a patient-level meta-analysis. Ann Intern Med 139: 244-252.
571	4. Hoefele J, Mayer K, Scholz M, Klein HG (2011) Novel PKD1 and PKD2 mutations in autosomal
572	dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 26: 2181-2188.
573	5. Wu G, Tian X, Nishimura S, Markowitz GS, D'Agati V, et al. (2002) Trans-heterozygous Pkd1 and
575	PKd2 mutations modify expression of polycystic kidney disease. Hum Mol Genet 11: 1845-
576	6 Villard E Tiret I. Visvikis S. Rakotovao R. Cambien E. et al. (1996) Identification of new
577	polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their
578	relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet
579	58: 1268-1278.
580	7. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, et al. (1990) An insertion/deletion
581	polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of
582	serum enzyme levels. J Clin Invest 86: 1343-1346.
585 584	8. Haas M, Yilmaz N, Schmidt A, Neyer U, Ameriz K, et al. (1998) Angiotensin-convening enzyme
585	enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of
586	Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 21: 66-69.
587	9. Kleij FGHVD (2002) Angiotensin-converting enzyme gene insertion/deletion polymorphism and
588	renal disease. Groningen: University of Groningen.
589	10. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A (2000) ACE gene polymorphism in
590 501	cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler
591	THIOMD VASC BIOLZU: 484-492. 11. Osono E. Kuribara S. Havama N. Sakurai V. Obwada K. et al. (1998) Insertion/delation
593	polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with
594	end-stage renal disease. Am J Kidney Dis 32: 725-730.
595	12. Scharplatz M, Puhan MA, Steurer J, Bachmann LM (2004) What is the impact of the ACE gene
596	insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE
597	inhibitors?Protocol of a systematic review. BMC Med Genet 5: 23.
598 500	13. Yu ZY, Chen LS, Zhang LC, Zhou TB (2012) Meta-analysis of the relationship between ACE I/D
599 600	yene polymorphism and end-stage renardisease in patients with diabetic hephropathy.
601	14 Shen W Jiang XX Li YW He Q (2019) I/D polymorphism of ACE and risk of diabetes-related
602	end-stage renal disease: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci
603	23: 1652-1660.
604	15. Zmorzynski S, Szudy-Szczyrek A, Popek-Marciniec S, Korszen-Pilecka I, Wojcierowska-Litwin M,
605	et al. (2019) ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the
606	Increased Risk of Multiple Myeloma. Front Oncol 9: 44.
608	or centional longevity: a meta-analysis. Againg Res Rev 12: 1079-1087
609	17. Narain Y. Yip A. Murphy T. Bravne C. Easton D. et al. (2000) The ACE gene and Alzheimer's
610	disease susceptibility. J Med Genet 37: 695-697.
611	18. Papadimitriou ID, Lucia Á, Pitsiladis YP, Pushkarev VP, Dyatlov DA, et al. (2016) ACTN3 R577X
612	and ACE I/D gene variants influence performance in elite sprinters: a multi-cohort study. BMC
613	Genomics 17: 285.
614 615	19. Chung CM, Wang RY, Chen JW, Fann CS, Leu HB, et al. (2010) A genome-wide association
616	Study identifies new loci for ACE activity, potential implications for response to ACE inhibitor. Pharmacogenomics J 10: 537-544
617	20. Woo YM. Bae JB. Oh YH. Lee YG. Lee MJ. et al. (2014) Genome-wide methylation profiling of
618	ADPKD identified epigenetically regulated genes associated with renal cvst development.
619	Hum Genet 133: 281-297.

620	21. Pereira TV, Nunes AC, Rudnicki M, Magistroni R, Albertazzi A, et al. (2006) Influence of ACE I/D
621	gene polymorphism in the progression of renal failure in autosomal dominant polycystic
622	kidney disease: a meta-analysis. Nephrol Dial Transplant 21: 3155-3163.
623	22. Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis
624	program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-
625	191.
626	23. Clark MF, Baudouin SV (2006) A systematic review of the quality of genetic association studies in
627	human sepsis. Intensive Care Med 32: 1706-1712.
628	24. Konoshita T, Miyagi K, Onoe T, Katano K, Mutoh H, et al. (2001) Effect of ACE gene
629	polymorphism on age at renal death in polycystic kidney disease in Japan. Am J Kidney Dis
630	37: 113-118.
631	25. Lee KB, Kim UK, Lee CC (2000) Association of the ACE gene polymorphism with the progression
632	of autosomal dominant polycystic kidney disease. J Korean Med Sci 15: 431-435.
033	26. Ramanathan G, Ghosh S, Elumaiai R, Periyasamy S, Lakkakula BV (2016) Influence of
034	angiotensin converting enzyme (ACE) gene rs4362 polymorphism on the progression of
635	kidney failure in patients with autosomal dominant polycystic kidney disease (ADPKD). Indian
627	J Med Res 143: 748-755.
628	27. Tripathi G, Dharmani P, Khan F, Sharma KK, Pandirikkai V, et al. (2006) High prevalence of ACE
620	DD genolype among north indian end stage renal disease patients. Divid Nephrol 7. 15.
640	20. The and foilure among parth Indian ESPD patients. Clin Piceborr 41: 525-521
640 641	20 Llomasu I. Nakaoka A. Kawasaki H. Ishikawa I. Yashina Y. at al. (1907) Association between
642	29. Demasu J, Nakaoka A, Nawasaki H, Ishikawa I, Toshiko T, et al. (1997) Association between
643	dominant polycystic kidney disease. Life Sci 60: 2139-2144
644	30 Baboolal K Bavine D Daniels I Williams N Holmans P et al. (1997) Association of the
645	angiotensin L converting enzyme gene deletion polymorphism with early onset of ESRE in
646	PKD1 adult polycystic kidney disease. Kidney Int 52: 607-613
647	31. Buraczynska M. Ksiazek P. Drop A. Zaluska W. Spasiewicz D. et al. (2006) Genetic
648	polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial
649	Transplant 21: 979-983.
650	32. Ecder T, McFann KK, Raynolds MV, Schrier RW (2003) No effect of angiotensin-converting
651	enzyme gene polymorphism on disease progression and left ventricular hypertrophy in
652	autosomal dominant polycystic kidney disease. Am J Nephrol 23: 466-470.
653	33. Gumprecht J, Zychma MJ, Karasek D, Grzeszczak W (2007) ACE gene I/D polymorphism and the
654	presence of renal failure or hypertension in autosomal dominant polycystic kidney disease
655	(ADPKD). Nephrol Dial Transplant 22: 1483.
656	34. Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P (2001) Genetic polymorphisms of the renin-
657	angiotensin-aldosterone system in end-stage renal disease. Kidney Int 60: 46-54.
658	35. Merta M, Reiterova J, Stekrova J, Rysava R, Rihova Z, et al. (2003) Influence of the alpha-
659	adducin and ACE gene polymorphism on the progression of autosomal-dominant polycystic
660	kidney disease. Kidney Blood Press Res 26: 42-49.
661	36. Perez-Oller L, Torra R, Badenas C, Mila M, Darnell A (1999) Influence of the ACE gene
662	polymorphism in the progression of renal failure in autosomal dominant polycystic kidney
663	disease. Am J Kidney Dis 34: 2/3-2/8.
664	37. Persu A, El-Khattabi O, Messiaen I, Pirson Y, Chauveau D, et al. (2003) Influence of ACE (I/D)
665	and G460W polymorphism of alpha-adducin in autosomal dominant polycystic kidney
000 667	disease. Nephroi Dial Transplant 18: 2032-2038.
668	38. Saggar-Malik AK, Alzal AK, Swissman JS, Bland M, Sagnella GA, et al. (2000) Lack of
660	association of ACE/anglotensinogen genotype with renarrunction in autosomal dominant
670	29 Schiavello T Burke V Boadanova N Jasik P Melsom S et al. (2001) Angiotensin-converting
671	enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney
672	disease Nenbrol Dial Transplant 16: 2323-2327
673	40 van Diik MA Breuning MH Peters D.I. Chang PC (2000) The ACE insertion/deletion
674	polymorphism has no influence on progression of renal function loss in autosomal dominant
675	polycystic kidney disease. Nephrol Dial Transplant 15: 836-839.
676	41. Wanic-Kossowska M, Posnik B, Kobelski M, Pawliczak E. Pawlaczvk K. et al. (2014) The
677	polymorphism of the ACE gene affects left ventricular hypertrophy and causes disturbances in
678	left ventricular systolic/diastolic function in patients with autosomal dominant polycystic kidney
679	disease. ScientificWorldJournal 2014: 707658.

680	42. Chen H, Cohen, P, and Chen, S, (2010) How Big is a Big Odds Ratio? Interpreting the
681	Magnitudes of Odds Ratios in Epidemiological Studies. Communications in Statistics—
682 683 684	43. Goodman SN (2005) Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials 2: 282-290: discussion 301-284, 364-278
685	 44. Goodman SN (1999) Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern
686	Med 130: 1005-1013.
687	45. Royall R (1997) Statistical evidence: The likelihood paradigm. London: Chapman and Hall.
688	46. Higgins JP (2008) Commentary: Heterogeneity in meta-analysis should be expected and
690	 47. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-
691	analyses. Bmi 327: 557-560
692	 Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:
693	1539-1558.
694 695	49. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
696	50. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
697	51. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical
698	trials. Stat Med 7: 889-894.
699	52. Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in
700	meta-analyses: a large survey. CMA L176: 1091-1096
701 702	 53. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
703	54. Pfeiffer T, Bertram L, Ioannidis JP (2011) Quantifying selective reporting and the Proteus
704	phenomenon for multiple datasets with similar bias. PLoS One 6: e18362.
705 706	55. Dumas-Mallet E, Button KS, Boraud T, Gonon F, Munafo MR (2017) Low statistical power in biomedical science: a review of three human research domains. R Soc Open Sci 4: 160254.
707 708 709	 56. Crisan D, Carr J (2000) Angiotensin I-converting enzyme: genotype and disease associations. J Mol Diagn 2: 105-115. 57. Braliou GG, Grigoriadou AM, Kontou PL, Bagos PG (2014) The role of genetic polymorphisms of
710 711	the Renin-Angiotensin System in renal diseases: A meta-analysis. Comput Struct Biotechnol J 10: 1-7.
712	58. Zhou TB, Yin SS, Qin YH (2014) Association between angiotensin-converting enzyme
713	insertion/deletion gene polymorphism and end-stage renal disease susceptibility. J Renin
714 715 716	Angiotensin Aldosterone Syst 15: 22-31. 59. Jardine AG, Padmanabhan N, Connell JM (1998) Angiotensin converting enzyme gene
710 717 718	60. Navis G, van der Kleij FG, de Zeeuw D, de Jong PE (1999) Angiotensin-converting enzyme gene
719	 Mizuiri S, Hemmi H, Kumanomidou H, Iwamoto M, Miyagi M, et al. (2001) Angiotensin-converting
720	enzyme (ACE) I/D genotype and renal ACE gene expression. Kidney Int 60: 1124-1130.
721	62. Davis GK, Millner RW, Roberts DH (2000) Angiotensin converting enzyme (ACE) gene expression
722	in the human left ventricle: effect of ACE gene insertion/deletion polymorphism and left
723 724 725	ventricular function. Eur J Heart Fail 2: 253-256. 63. Studer R, Reinecke H, Muller B, Holtz J, Just H, et al. (1994) Increased angiotensin-I converting
725 726 727	polymerase chain reaction. J Clin Invest 94: 301-310. 64. Grobe II. Grobe Cl. Beltz TG. Westphal SG. Morgan DA, et al. (2010) The brain Renin-
728 729	angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance. Cell Metab 12: 431-442.
730	65. Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and
731	pharmacology. Trends Pharmacol Sci 23: 177-183.
732 733	66. Rigat B, Hubert C, Corvol P, Soubrier F (1992) PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl
735 736	 carboxypeptidase 1). Nucleic Acids Res 20: 1433. 67. Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, et al. (1988) Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 34: 683-690.
737	 68. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, et al. (2012) Analysis of baseline
738	parameters in the HALT polycystic kidney disease trials. Kidney Int 81: 577-585.

- 69. Hian CK, Lee CL, Thomas W (2016) Renin-Angiotensin-Aldosterone System Antagonism and
 Polycystic Kidney Disease Progression. Nephron 134: 59-63.
- 741 70. Poole C (2001) Low P-values or narrow confidence intervals: which are more durable?
 742 Epidemiology 12: 291-294.
- 743 71. Moore JH, Williams SM (2002) New strategies for identifying gene-gene interactions in
 744 hypertension. Ann Med 34: 88-95.
- 745 72. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC (2006) ACE
 746 polymorphisms. Circ Res 98: 1123-1133.
- 747
- 748

749 Author contributions

Conceptualization: NP, PT Data curation: NP, PT and YP Formal analysis: NP, PT and YP Investigation: NP, PT Methodology: NP, PT and YP Project administration: NP, PT Resources: PT, NP and AT Software: NP, PT Supervision: NP Validation: NP, PT, YP and AT Visualization: NP, PT and YP Writing – original draft: NP, PT Writing – review & editing: NP, PT, YP and AT

750

753

751 Data availability statement

All relevant data are within the paper and its Supporting information files

754 Funding

- 755 This research did not receive any specific grant from funding agencies in the public, commercial, or
- 756 not-for-profit sectors
- 757

758 Competing interests

- 759 The authors have no conflicts of interest to declare
- 760

761 Supporting information

762 S1 List Excluded articles DOCX 763 S1 Table Ouantitative DOCX 764 PRISMA checklist S2 Table DOCX 765 S3 Table Genetic checklist DOCX S5 Data Raw data code XLS

March 12, 2019

"angiotensin converting enzyme", *"ACE"*, "ADPKD", "autosomal dominant polycystic kidney disease" and "polymorphism"



	Case		Contr	ol	Weight	C			
Study Year	Events	Total	Events	Total	%	Rando			
Konoshita 2001	9	76	1	27	8.9	3.49 [0			
Lee 2000*	7	24	30	84	16.6	0.74			
Ramanathan 2016*	20	102	21	106	19.0	0.99			
Tripathi 2006*	37	127	10	150	18.5	5.76 [2			
Tripathi 2008*	56	184	42	569	20.6	5.49			
Uemasu 1997	44	100	5	47	16.4	6.60 [2			
Total (95% CI) 613 983 100.0									
Total events	173		109						
Heterogeneity: τ² = 0.80; χ² = 29.79; df = 5 (P ^b < 0.0001); ² = 83%									
Test for overall effect: $Z = 2.49 (P^a = 0.01)^{**}$									







	Case	9	Contr	ol	Weight	00		
Study Year	Events	Total	Events	Total	%	Fixe		
Konoshita 2001	9	76	1	27	5.0	3.49 [0.		
Tripathi 2006*	37	127	10	150	25.1	5.76 [2.		
Tripathi 2008*	56	184	42	569	55.2	5.49 [3		
Uemasu 1997	44	100	5	47	14.7	6.60 [2.		
Total (95% CI)		487		793	100.0	5.62 [3		
Total events	146		58					
Heterogeneity: χ² = 0.31; df = 3 (Ρ ^ь = 0.96); ² = 0%								
Test for overall effect: Z = 9.46 (P ^a < 0.00001)								







0%



100%